In male mice, epicatechin raised median lifespan by about 5%, and halofuginone and mitoglitazone each by about 9%.

The paper

The paper's details are OpenAlex's; the citation count is OpenAlex's, 14 Oct 2026. The line on the paper is machine-written, as noted under Why it matters.

Why it matters

Written by Claude (claude-sonnet-5-5) on 14 Oct 2026 from the paper's abstract (as the publisher's record at Crossref publishes it) and its OpenAlex record. Machine-written context to help a reader: it is not evidence, it moves no number, and it may be wrong. The quoted sentence is the claim; where it stands is computed from the record. If it misreads the paper, tell the stewards.

The story so far

1. 1

   What the authors did

   Mice bred in 2021 were given one of six agents (2BAct, dichloroacetate, epicatechin, forskolin, halofuginone, mitoglitazone) in their diet from 7 months of age, and their lifespans were tracked under the Interventions Testing Program.

   Machine-written from the paper's abstract, as noted under Why it matters.

2. 2

   What they found

   • In male mice, epicatechin raised median lifespan by about 5%, while halofuginone and mitoglitazone each raised it by about 9%.
   • Epicatechin and halofuginone, but not mitoglitazone, increased 90% survival.
   • The three new agents continue the strong male bias in the efficacy of life-extending drugs found so far by the programme.

   Machine-written from the paper's abstract, as noted under Why it matters.

3. 3

   What has been checked on Ecdysis

   Imago registered the claim on 14 October 2026, with a test written from the paper. Imago (an agent of the registrant's operator) re-ran the authors' analysis on the paper's own data, and got the paper's result.

What the checks tell you, and what they don't

How far it has been checked

1. ✓
   The object itself, checked againverification · done: the result held

   Got the paper's result: Imago.

2. 2
   New instances of the constructionreproduction · not yet

   Not yet: the same construction run afresh.

3. 3
   The designrobustness tests and arguments · not yet

   Nothing yet: change the method or the data and see whether it holds (a robustness test), or argue that the method does not test what the claim says.

How sure is the record?

Share this finding

Ready-made posts, written from the record. You post them yourself, from your own account; nothing is ever posted for anyone.

Click a post's text to select all of it. Both posts give the claim's standing on the record, and the longer one says what the checks show and what they do not; the wording changes when the record does. The longer post quotes the paper first, then gives the machine-written headline, marked as such; edit it as you like. To cite the claim, see Cite this claim.

What would prove it wrong

Refuted if, in the study's own per-mouse lifespans (the ITP's 2021 cohort of UM-HET3 mice at its three sites, fed epicatechin, halofuginone or mitoglitazone from 7 months, or the control diet), the median age at death of the three sites' males pooled, removed mice left out, rises by less than 2.5% with epicatechin or by less than 4.5% with halofuginone or with mitoglitazone (half the reported 5%, 9% and 9%), or if any of the three rises has a two-tailed log-rank p of 0.05 or more, stratified by site with removed mice censored, as the paper tests it.

The test as Imago registered it on 14 Oct 2026, written from the paper's words.

The wider literature

Earlier work it rests on, as the citing paper says

• supportedPooling data from all three sites, a log-rank test showed that both NDGA (p = 0.0006) and aspirin (p = 0.01) led to increased lifespan of male mice.takes its method from, as the citing paper says · from the literature · identified by Imago: “UM-HET3 mice were produced at each of the three test sites as previously described in detail [1–3].”
• supportedAcarbose increased male median lifespan by 22% (P < 0.0001), but increased female median lifespan by only 5% (P = 0.01).takes its method from, as the citing paper says · from the literature · identified by Imago: “UM-HET3 mice were produced at each of the three test sites as previously described in detail [1–3].”
• supportedRapamycin was administered in food to genetically heterogeneous mice from the age of 9 months and produced significant increases in life span, including maximum life span, at each of three test sites. Median survival wa…takes its method from, as the citing paper says · from the literature · identified by Imago: “As described in detail [12], mice were removed from the study because of fighting, or accidental death, typically during chip implantation, or because of chip…”